Ontorpacept Biosimilar – Anti-CD47 fusion protein – Research Grade

Description of Ontorpacept Biosimilar - Anti-CD47 fusion protein - Research Grade

Title: Understanding the Structure and Function of Ontorpacept Biosimilar – Anti-CD47 Fusion Protein

Introduction

Ontorpacept is a biosimilar anti-CD47 fusion protein that has gained significant attention in the field of immunotherapy. This innovative drug has shown promising results in preclinical studies and is currently being evaluated in clinical trials for its potential therapeutic applications. In this article, we will delve into the structure, activity, and potential applications of Ontorpacept.

Structure of Ontorpacept

Ontorpacept is a fusion protein that consists of two components – a humanized anti-CD47 antibody and a modified human IgG1 Fc region. The anti-CD47 antibody portion specifically binds to the CD47 protein, which is overexpressed in various types of cancer cells. The Fc region, on the other hand, provides the necessary effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).

The anti-CD47 antibody used in Ontorpacept is a humanized version of the monoclonal antibody B6H12, which was originally developed by researchers at Stanford University. This antibody has been extensively studied and has shown promising results in targeting CD47-expressing cancer cells. The Fc region is modified to enhance its binding affinity to Fc gamma receptors, thereby increasing its potency in inducing immune-mediated cell death.

Mechanism of Action

The primary mechanism of action of Ontorpacept is through the blockade of the CD47 protein. CD47 is a cell surface protein that is upregulated in cancer cells to evade immune surveillance. It interacts with the signal regulatory protein alpha (SIRPα) on macrophages, resulting in a “don’t eat me” signal that prevents the macrophages from engulfing the cancer cells. By binding to CD47, Ontorpacept disrupts this interaction and allows the macrophages to phagocytose the cancer cells, leading to their destruction.

In addition to CD47 blockade, Ontorpacept also exerts its effects through the Fc region. The Fc region binds to Fc gamma receptors on immune cells, triggering a cascade of events that result in the destruction of cancer cells. This dual mechanism of action makes Ontorpacept a potent therapeutic agent for targeting CD47-expressing cancer cells.

Potential Applications

Ontorpacept has shown promising results in preclinical studies, demonstrating its efficacy in various types of cancer, including acute myeloid leukemia, non-Hodgkin’s lymphoma, and solid tumors such as breast, ovarian, and lung cancer. It has also shown potential in combination with other cancer therapies, such as chemotherapy and checkpoint inhibitors.

In addition to its anti-

cancer properties, Ontorpacept has also shown promise in other disease areas. CD47 is overexpressed in many autoimmune diseases, and preclinical studies have shown that Ontorpacept can inhibit the development of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. It has also shown potential in the treatment of fibrotic diseases, where CD47 plays a role in promoting tissue fibrosis.

Conclusion

Ontorpacept is a novel biosimilar anti-CD47 fusion protein that has shown great potential in the field of immunotherapy. Its unique structure and dual mechanism of action make it a promising therapeutic agent for various types of cancer and other diseases. With ongoing clinical trials, we can expect to see more data on the safety and efficacy of Ontorpacept, which could potentially lead to its approval as a new treatment option for patients in need.